logo

KYNB

Kyntra Bio·NASDAQ
--
--(--)
--
--(--)

KYNB fundamentals

Kyntra Bio (KYNB) released its earnings on Nov 10, 2025: revenue was 1.08M (YoY -97.68%), missed estimates; EPS was 49.61 (YoY +1267.29%), beat estimates.
Revenue / YoY
1.08M
-97.68%
EPS / YoY
49.61
+1267.29%
Report date
Nov 10, 2025
KYNB Earnings Call Summary for Q3,2025
  • $220M China Sale: Extended cash runway to 2028, reducing debt by $75M and receiving $6.4M of $10M holdback.
  • FG-3246 Milestones: Phase II trial initiated with G-CSF prophylaxis; IST combo data due Q1 2026, interim Phase II results H2 2026.
  • Roxadustat Path: FDA-aligned Phase III protocol for lower-risk MDS; $50-60M trial cost, exploring partner funding.
  • Financial Health: Q3 2025 operating expenses down 86% YoY; $121.1M U.S. cash, no near-term liabilities beyond optional Phase III.
EPS
Revenue

Revenue & Expenses

KYNB has released its 2025 Q3 earnings report, with revenue of 1.08M, reflecting a YoY change of 774.80%, and net profit of 200.64M, showing a YoY change of 1274.41%. The Sankey diagram below clearly presents KYNB's revenue sources and cost distribution.

Key Indicators

Kyntra Bio (KYNB) key financial stats and ratios, covering profitability, financial health, and leverage.
Kyntra Bio (KYNB)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Kyntra Bio (KYNB)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Kyntra Bio (KYNB)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Kyntra Bio (KYNB) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Kyntra Bio (KYNB) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield